Simonetta Viviani - Concepedia

Author

Simonetta Viviani

Fondazione IRCCS Istituto Nazionale dei Tumori ORCID

Also Known As

Kirkwood, Amy A., S Viviani, S. Viviani, Simona Viviani, Simonetta Viviani, Viviani, Viviani, S.

205

Publications

7.2K

Citations

H-Index

Concepts

All Affiliations

Fondazione IRCCS Istituto Nazionale dei Tumori University of Milan Fondazione Humanitas per la Ricerca Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo Azienda Ospedaliera San Gerardo

About

Simonetta Viviani is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	35	2.1K
2	Health Sciences	9	9	282
3	Cellular Therapies	3	3	74
4	Clinical Immunology	3	3	118
5	Endocrinology	2	2	72

Simonetta Viviani

Publications

6.6K

Citations

H-Index

Page 1

	Year	Citations
Early Interim 2-[ <sup>18</sup> F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study Andrea Gallamini, Martin Hutchings, Luigi Rigacci, Journal of Clinical Oncology	2007	829
ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned Simonetta Viviani, Pier Luigi Zinzani, Alessandro Rambaldi, New England Journal of Medicine	2011	419
Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. Armando Santoro, Gianni Bonadonna, Pinuccia Valagussa, Journal of Clinical Oncology PathologyPharmacotherapyMetronomic ChemotherapyHematological MalignancyRadiation Medicine	1987	380
Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD Simonetta Viviani, Armando Santoro, G. Ragni, European Journal of Cancer and Clinical Oncology Comparative ResultsCombination ChemotherapyMedicineMetronomic TherapyGynecology	1985	370
ABVD Plus Subtotal Nodal Versus Involved-Field Radiotherapy in Early-Stage Hodgkin's Disease: Long-Term Results Gianni Bonadonna, V. Bonfante, Simonetta Viviani, Journal of Clinical Oncology	2004	336
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale Andrea Gallamini, Sally F. Barrington, Alberto Biggi, Haematologica	2014	249
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee, Blood	2018	237
Gemcitabine in the Treatment of Refractory Hodgkin’s Disease: Results of a Multicenter Phase II Study Armando Santoro, Henning Bredenfeld, Liliana Devizzi, Journal of Clinical Oncology	2000	228
Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma Enrico Tiacci, Erik Ladewig, Gianluca Schiavoni, Blood	2018	221
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial Andrea Gallamini, Corrado Tarella, Simonetta Viviani, Journal of Clinical Oncology	2018	193

Page 1